Recombinant Human PAD1 Protein，His

PAD1 (Peptidylarginine deiminase 1) is an enzyme that plays a critical role in the post-translational modification of proteins through a process known as citrullination, where the amino acid arginine is converted into citrulline. This modification significantly influences various biological processes, including gene regulation, protein interactions, and immune responses. PAD1 is particularly important in the context of autoimmune diseases, such as rheumatoid arthritis, where abnormal citrullination patterns can trigger inappropriate immune reactions. Research has shown that PAD1 is expressed in various tissues, including the skin and immune cells, and its dysregulation can be linked to inflammatory conditions. Scientists are actively investigating PAD1 not only to understand its fundamental biological roles but also to explore its potential as a therapeutic target. By studying PAD1 and its effects on protein function, researchers aim to develop new strategies for treating diseases characterized by pathological citrullination, paving the way for innovative treatments that could alleviate symptoms and modify disease progression. Advances in recombinant protein technology have further enabled the production of PAD1 for in-depth studies, facilitating biochemical assays and structural analyses that enhance our understanding of its mechanism of action. Thus, PAD1 continues to be a significant focus in biomedical research, particularly in elucidating its contributions to health and disease.